The ubiquitin system regulates essential cellular processes in eukaryotes. Ubiquitin is ligated to substrate proteins as monomers or chains and the topology of ubiquitin modifications regulates substrate interactions with specific proteins. Thus ubiquitination directs a variety of substrate fates including proteasomal degradation1. Deubiquitinase enzymes cleave ubiquitin from substrates and are implicated in disease2; for example, ubiquitin-specific protease-7 (USP7) regulates stability of the p53 tumour suppressor and other proteins critical for tumour cell survival3. However, developing selective deubiquitinase inhibitors has been challenging4 and no co-crystal structures have been solved with small-molecule inhibitors. Here, using nuclear magnetic resonance-based screening and structure-based design, we describe the development of selective USP7 inhibitors GNE-6640 and GNE-6776. These compounds induce tumour cell death and enhance cytotoxicity with chemotherapeutic agents and targeted compounds, including PIM kinase inhibitors. Structural studies reveal that GNE-6640 and GNE-6776 non-covalently target USP7 12 Å distant from the catalytic cysteine. The compounds attenuate ubiquitin binding and thus inhibit USP7 deubiquitinase activity. GNE-6640 and GNE-6776 interact with acidic residues that mediate hydrogen-bond interactions with the ubiquitin Lys48 side chain5, suggesting that USP7 preferentially interacts with and cleaves ubiquitin moieties that have free Lys48 side chains. We investigated this idea by engineering di-ubiquitin chains containing differential proximal and distal isotopic labels and measuring USP7 binding by nuclear magnetic resonance. This preferential binding protracted the depolymerization kinetics of Lys48-linked ubiquitin chains relative to Lys63-linked chains. In summary, engineering compounds that inhibit USP7 activity by attenuating ubiquitin binding suggests opportunities for developing other deubiquitinase inhibitors and may be a strategy more broadly applicable to inhibiting proteins that require ubiquitin binding for full functional activity.

  • Subscribe to Nature for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


Primary accessions

Biological Magnetic Resonance Data Bank


  1. 1.

    & The ubiquitin code. Annu. Rev. Biochem. 81, 203–229 (2012)

  2. 2.

    , & The demographics of the ubiquitin system. Trends Cell Biol. 25, 417–426 (2015)

  3. 3.

    & The multifaceted roles of USP7: new therapeutic opportunities. Cell Biochem. Biophys. 60, 61–68 (2011)

  4. 4.

    et al. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nat. Commun. 5, 4763 (2014)

  5. 5.

    et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111, 1041–1054 (2002)

  6. 6.

    et al. Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428, 486–487 (2004)

  7. 7.

    . et al. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 29, 1270–1279 (2010)

  8. 8.

    et al. Structural characterization of interaction between human ubiquitin-specific protease 7 and immediate-early protein ICP0 of herpes simplex virus-1. J. Biol. Chem. 290, 22907–22918 (2015)

  9. 9.

    et al. Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation. Nat. Commun. 6, 7023 (2015)

  10. 10.

    et al. Ubiquitin-specific protease-7 inhibition impairs Tip60-dependent Foxp3+ T-regulatory cell function and promotes antitumor immunity. EBioMedicine 13, 99–112 (2016)

  11. 11.

    et al. USP7 acts as a molecular rheostat to promote WASH-dependent endosomal protein recycling and is mutated in a human neurodevelopmental disorder. Mol. Cell 59, 956–969 (2015)

  12. 12.

    et al. Deubiquitylases from genes to organism. Physiol. Rev. 93, 1289–1315 (2013)

  13. 13.

    Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 12, 94 (2014)

  14. 14.

    & DUBs, the regulation of cell identity and disease. Biochem. J. 467, 191 (2015)

  15. 15.

    & MDM2’s social network. Oncogene 33, 4365–4376 (2014)

  16. 16.

    & p53 in the DNA-damage-repair process. Cold Spring Harb. Perspect. Med. 6, a026070 (2016)

  17. 17.

    , & For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer 11, 23–34 (2011)

  18. 18.

    , , , , & Pyrazol-4-yl-heterocyclyl-carboxamide compounds as Pim kinase inhibitors and their preparation. US patent 8, 614,206 B2 (2013)

  19. 19.

    , , , & A general chemical ligation approach towards isopeptide-linked ubiquitin and ubiquitin-like assay reagents. ChemBioChem 13, 293–297 (2012)

  20. 20.

    et al. The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chem. Biol. 18, 1550–1561 (2011)

  21. 21.

    et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat. Commun. 5, 3630 (2014)

  22. 22.

    & Protein-linked ubiquitin chain structure restricts activity of deubiquitinating enzymes. J. Biol. Chem. 286, 45186–45196 (2011)

  23. 23.

    & Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu. Rev. Biochem. 81, 291–322 (2012)

  24. 24.

    et al. A resource for cell line authentication, annotation and quality control. Nature 520, 307–311 (2015)

  25. 25.

    et al. Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Nature 528, 370–375 (2015)

  26. 26.

    et al. Reproducible pharmacogenomic profiling of cancer cell line panels. Nature 533, 333–337 (2016)

  27. 27.

    et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat. Biotechnol. 34, 155–163 (2016)

  28. 28.

    et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659–666 (2009)

  29. 29.

    et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407–416 (2016)

  30. 30.

    et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem. Biol. 19, 467–477 (2012)

Download references


We thank W. Fairbrother, L. Frick, S. Fong, E. Helgason, T. Hunsaker, C. Lam, B. Liederer, M. Merchant, J. Nonomiya, J. Peng, T. Pham, L. Rangell, R. Rodriguez, U. Segal, R. Tong, L. Wang, R. Gennis, T. Iwasaki, the Genentech Protein Expression, Cell Central, gCSI, and Sequencing groups, and the Boston Biochem team for reagents and collaborations. Use of the Stanford Synchrotron Radiation Lightsource, SLAC National Accelerator Laboratory, was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences under contract number DE-AC02-76SF00515. The SSRl Structural Molecular Biology Program was supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (including P41GM103393). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of National Institute of General Medical Sciences or the National Institutes of Health.

Author information

Author notes

    • Lorna Kategaya
    • , Paola Di Lello
    •  & Lionel Rougé

    These authors contributed equally to this work.


  1. Department of Discovery Oncology, Genentech, South San Francisco, California 94080, USA

    • Lorna Kategaya
    • , Eva Lin
    • , John-Paul Upton
    • , Sumit Prakash
    • , Johanna Heideker
    • , Mark McCleland
    • , Scott E. Martin
    •  & Ingrid E. Wertz
  2. Department of Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA

    • Lorna Kategaya
    • , John-Paul Upton
    • , Sumit Prakash
    • , Johanna Heideker
    • , Mark McCleland
    •  & Ingrid E. Wertz
  3. Department of Structural Biology, Genentech, South San Francisco, California 94080, USA

    • Paola Di Lello
    • , Lionel Rougé
    • , Jeremy Murray
    •  & Till Maurer
  4. Department of Discovery Chemistry, Genentech, South San Francisco, California 94080, USA

    • Richard Pastor
    • , Frederick Cohen
    • , Chudi Ndubaku
    • , Xiaojing Wang
    •  & Vickie Tsui
  5. Department of Biochemical and Cellular Pharmacology, Genentech, South San Francisco, California 94080, USA

    • Kevin R. Clark
    • , Jason Drummond
    • , Tracy Kleinheinz
    • , Maureen H. Beresini
    •  & Robert A. Blake
  6. MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK

    • Maria Stella Ritorto
    •  & Dario R. Alessi
  7. Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne NE2 1HH, UK

    • Matthias Trost
  8. Department of Protein Chemistry, Genentech, South San Francisco, California 94080, USA

    • Travis W. Bainbridge
    • , Michael C. M. Kwok
    •  & James A. Ernst
  9. Department of Microchemistry, Proteomics, and Lipidomics, Genentech, South San Francisco, California 94080, USA

    • Taylur P. Ma
    •  & Kebing Yu
  10. Boston Biochem, 840 Memorial Drive, Cambridge, Massachusetts 02139, USA

    • Zachary Stiffler
    • , Bradley Brasher
    •  & Carsten Schwerdtfeger
  11. Department of Pharmaceutical Chemistry and Small Molecule Discovery Center, University of California, San Francisco, San Francisco, California 94143, USA

    • Yinyan Tang
    • , Priyadarshini Jaishankar
    • , Brian R. Hearn
    • , Adam R. Renslo
    •  & Michelle R. Arkin
  12. Department of Research Pathology, Genentech, South San Francisco, California 94080, USA

    • Frank Peale
  13. Department of Bioinformatics and Computational Biology, Genentech, South San Francisco, California 94080, USA

    • Florian Gnad
    • , Matthew T. Chang
    • , Christiaan Klijn
    •  & William F. Forrest
  14. Department of Translational Oncology, Genentech, South San Francisco, California 94080, USA

    • Elizabeth Blackwood


  1. Search for Lorna Kategaya in:

  2. Search for Paola Di Lello in:

  3. Search for Lionel Rougé in:

  4. Search for Richard Pastor in:

  5. Search for Kevin R. Clark in:

  6. Search for Jason Drummond in:

  7. Search for Tracy Kleinheinz in:

  8. Search for Eva Lin in:

  9. Search for John-Paul Upton in:

  10. Search for Sumit Prakash in:

  11. Search for Johanna Heideker in:

  12. Search for Mark McCleland in:

  13. Search for Maria Stella Ritorto in:

  14. Search for Dario R. Alessi in:

  15. Search for Matthias Trost in:

  16. Search for Travis W. Bainbridge in:

  17. Search for Michael C. M. Kwok in:

  18. Search for Taylur P. Ma in:

  19. Search for Zachary Stiffler in:

  20. Search for Bradley Brasher in:

  21. Search for Yinyan Tang in:

  22. Search for Priyadarshini Jaishankar in:

  23. Search for Brian R. Hearn in:

  24. Search for Adam R. Renslo in:

  25. Search for Michelle R. Arkin in:

  26. Search for Frederick Cohen in:

  27. Search for Kebing Yu in:

  28. Search for Frank Peale in:

  29. Search for Florian Gnad in:

  30. Search for Matthew T. Chang in:

  31. Search for Christiaan Klijn in:

  32. Search for Elizabeth Blackwood in:

  33. Search for Scott E. Martin in:

  34. Search for William F. Forrest in:

  35. Search for James A. Ernst in:

  36. Search for Chudi Ndubaku in:

  37. Search for Xiaojing Wang in:

  38. Search for Maureen H. Beresini in:

  39. Search for Vickie Tsui in:

  40. Search for Carsten Schwerdtfeger in:

  41. Search for Robert A. Blake in:

  42. Search for Jeremy Murray in:

  43. Search for Till Maurer in:

  44. Search for Ingrid E. Wertz in:


L.K., E.L., J.-P.U., S.P., F.P., S.E.M., and I.E.W. performed cell viability and signalling studies, protein turnover and ubiquitination experiments, and independently replicated cellular data. P.D.L. and T.M. performed NMR studies; L.R. and J.M. performed X-ray crystallography and cross-validated data. J.D., T.K., T.W.B., M.C.M.K., Z.S., B.B., Y.T., M.R.A., J.A.E., C.S., and R.A.B. performed in vitro and cellular biochemical studies and independently replicated data. J.H., M.S.R., T.P.M., D.R.A., M.T., and K.Y. performed deubiquitinase selectivity profiling studies, and M.M. and E.B. performed in vivo studies and cross-validated data. K.R.C. and M.H.B. developed assays, and performed and analysed high-throughput screening studies. R.P., P.J., B.R.H., A.R.R., F.C., C.N., X.W., and V.T. performed compound design/synthesis. F.G., M.T.C., C.K., and W.F.F. performed bioinformatics/statistical analysis and replicated data. T.M. and I.E.W. coordinated studies. J.M., T.M., and I.E.W. wrote the manuscript. D.R.A. is supported by the UK Medical Research Council (grant MC_UU_12016/2).

Competing interests

L.K., P.D.L., L.R., R.P., K.R.C., J.D., T.K., E.L., J.-P.U., S.P., J.H., M.M., T.W.B., M.C.M.K., T.P.M., F.C., K.Y., F.P., F.G., M.T.C., C.K., E.B., S.E.M., W.F.F., J.A.E., C.N., X.W., M.H.B., V.T., R.A.B., J.M., T.M., and I.E.W. are or were Genentech employees. M.S.R. is a Pfizer employee.

Corresponding authors

Correspondence to Till Maurer or Ingrid E. Wertz.

Reviewer Information Nature thanks M. Rolfe, S. Scherer and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Supplementary information

PDF files

  1. 1.

    Reporting Summary

  2. 2.

    Supplementary Information

    This file contains Supplementary Figures 1-2, Supplementary Tables 1-2 and Supplementary Methods.

  3. 3.

    Supplementary Figures

    This file contains Supplementary Figures containing gel source data and graphs, and Supplementary Tables 1 and 2.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.